NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing treatments for brain cancers and other central nervous system (CNS) diseases. Its proprietary, patented drug-delivery platform is designed to transport therapeutics to the brain by bypassing the blood-brain barrier, a challenge that can prevent promising medicines from reaching their target. The company develops its own formulations and seeks to help pharmaceutical partners deliver both established and new therapies more effectively.

NeOnc’s products include NEO100, a clinical-grade intranasal formulation of perillyl alcohol (POH), a naturally occurring compound studied for recurrent gliomas, and NEO212, another candidate in its pipeline. The company also reports research into NEO400 and delivery approaches that may support the transport of other therapeutics. Its work spans research, clinical development, patents, and collaboration with medical professionals, with a focus on improving treatment possibilities for patients with brain tumors and other CNS conditions. NeOnc shares research articles, clinical-trial information, company news, and investor resources, and invites patients to learn about opportunities to participate in its trials.